co-presented by
ASSOCIATE SPONSORS
co-presented by
ASSOCIATE SPONSORS
Manchanda said he would like to hear from the management with regard to the distribution of the proceeds of the deal. If Claris' management decides to delist the company, it may opt for a share buyback as dividend payout involves distribution tax, he added.
Indian pharmaceutical companies Aurobindo and Intas are among the final contenders for Teva‘s generic drug business in UK. The strategy will help the companies expand their European business.
Speaking to CNBC-TV18, Arjun Handa, managing director & CEO of Claris Lifesciences said."We have had very productive meeting with the US FDA and are hopeful of resolving the issue very soon. We don’t see this as very big hurdle for the company."
